Paper Details

  1. Home
  2. Paper Details

Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.

Author: AgarwalAshok, PahalajaniGeetu, RainaRupesh, ZippeCraig

Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study evaluated the long-term effectiveness, side effects, and compliance rates of two types of drugs (luteinizing hormone-releasing hormone [LHRH] agonist and antiandrogen) that were used individually to treat patients with localized prostate cancer (T1-2). The study found that LHRH agonist monotherapy provided long-term durable control of localized prostate cancer (T1-2) and can be an effective treatment option for patients whose disease failed to respond to antiandrogen monotherapy.
Paper Details　
Original Abstract of the Article :
AIM: To evaluate the long-term effectiveness, side effects and compliance rates of two types of drugs (luteinizing hormone-releasing hormone [LHRH] agonist and antiandrogen) that were used individually to treat patients with localized prostate cancer (T1-2) at our institution. METHODS: Ninety-seven...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1745-7262.2007.00074.x

データ提供：米国国立医学図書館（NLM）

LHRH Agonist vs. Antiandrogen Monotherapy in Prostate Cancer

Prostate cancer, a prevalent disease, poses a significant challenge for healthcare providers. This research compares the long-term effectiveness of two distinct treatment approaches for localized prostate cancer (T1-2): luteinizing hormone-releasing hormone (LHRH) agonist monotherapy and antiandrogen monotherapy. The authors conducted a retrospective study examining the outcomes of elderly men who received either LHRH agonist or antiandrogen therapy. This study provides valuable insights into the long-term efficacy and side effect profiles of these treatment options for localized prostate cancer.

LHRH Agonist Offers Durable Control of Prostate Cancer

The study found that LHRH agonist monotherapy demonstrated superior long-term control of localized prostate cancer compared to antiandrogen monotherapy. The LHRH group experienced significantly fewer cases of prostate-specific antigen (PSA) elevation, indicating better disease control. Furthermore, the study highlights the potential of LHRH therapy as a salvage option for patients who have failed antiandrogen treatment.

Understanding Treatment Options for Prostate Cancer

This research emphasizes the importance of carefully considering treatment options for prostate cancer based on individual patient characteristics and disease stage. The study provides valuable information for healthcare professionals and patients alike, allowing for more informed decision-making regarding treatment choices for localized prostate cancer.

Dr.Camel's Conclusion

Imagine a camel trekking through the vast desert, encountering various obstacles and challenges. This research is like a map, guiding us through the intricate landscape of prostate cancer treatments. The study reveals the strengths and limitations of different treatment options, allowing us to choose the path that best suits our individual needs. This research underscores the ongoing quest for effective and personalized treatments for prostate cancer.

Date :
  1. Date Completed 2007-05-16
  2. Date Revised 2022-03-11
Further Info :

Pubmed ID

17334592

DOI: Digital Object Identifier

10.1111/j.1745-7262.2007.00074.x

Related Literature

Article Analysis
・Side Effects of nilutamide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.